中文翻译
批评很中肯。我最初在 $NBIS 86美元时发布观点，即便在125美元我仍会买入。 我未曾预期一家远期年度经常性收入(ARR)达70-90亿美元、同比增长超700%且拥有4家各自增长超100%的子公司企业，市值会暴跌40%至190亿美元。 存在1-3个月的短期定价错误（尤其是受宏观压力、套息交易平仓引发的高贝塔资产抛售及临时信贷收紧影响），但我预计所有高确信度标的在6-12个月内将跑赢大盘。
· 个股论点
回应批评，重申NBIS长期价值及短期错判逻辑。
涉及标的： $NBIS
英文原文
Very fair criticism. I first posted about $NBIS at $86 and would still be buying at $125. I did not expect a $7-9B forward ARR company growing 700%+ Y/Y, with 4 different subsidiary companies each growing 100%+ Y/Y to drop 40% to a $19B MC. There's things that are mispriced 1-3 month short term (especially with larger macro overhang with high-beta asset selloffs from carry trade unwind and temporary credit tightening) but I expect all my high conviction picks to outperform 6-12 months out.